Three-Month Symptom Profiles Among Symptomatic Adults With Positive and Negative Severe Acute Respiratory Syndrome Coronavirus 2 Tests: A Prospective Cohort Study From the INSPIRE Group

Abstract Background Long-term symptoms following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are a major concern, yet their prevalence is poorly understood. Methods We conducted a prospective cohort study comparing adults with SARS-CoV-2 infection (coronavirus disease-posi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical infectious diseases 2023-05, Vol.76 (9), p.1559-1566
Hauptverfasser: Spatz, Erica S, Gottlieb, Michael, Wisk, Lauren E, Anderson, Jill, Chang, Anna Marie, Gentile, Nicole L, Hill, Mandy J, Huebinger, Ryan M, Idris, Ahamed H, Kinsman, Jeremiah, Koo, Katherine, Li, Shu-Xia, McDonald, Samuel, Plumb, Ian D, Rodriguez, Robert M, Saydah, Sharon, Slovis, Benjamin, Stephens, Kari A, Unger, Elizabeth R, Wang, Ralph C, Yu, Huihui, Hota, Bala, Elmore, Joann G, Weinstein, Robert A, Venkatesh, Arjun
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Background Long-term symptoms following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are a major concern, yet their prevalence is poorly understood. Methods We conducted a prospective cohort study comparing adults with SARS-CoV-2 infection (coronavirus disease-positive [COVID+]) with adults who tested negative (COVID−), enrolled within 28 days of a Food and Drug Administration (FDA)-approved SARS-CoV-2 test result for active symptoms. Sociodemographic characteristics, symptoms of SARS-CoV-2 infection (assessed with the Centers for Disease Control and Prevention [CDC] Person Under Investigation Symptom List), and symptoms of post-infectious syndromes (ie, fatigue, sleep quality, muscle/joint pains, unrefreshing sleep, and dizziness/fainting, assessed with CDC Short Symptom Screener for myalgic encephalomyelitis/chronic fatigue syndrome) were assessed at baseline and 3 months via electronic surveys sent via text or email. Results Among the first 1000 participants, 722 were COVID+ and 278 were COVID−. Mean age was 41.5 (SD 15.2); 66.3% were female, 13.4% were Black, and 15.3% were Hispanic. At baseline, SARS-CoV-2 symptoms were more common in the COVID+ group than the COVID− group. At 3 months, SARS-CoV-2 symptoms declined in both groups, although were more prevalent in the COVID+ group: upper respiratory symptoms/head/eyes/ears/nose/throat (HEENT; 37.3% vs 20.9%), constitutional (28.8% vs 19.4%), musculoskeletal (19.5% vs 14.7%), pulmonary (17.6% vs 12.2%), cardiovascular (10.0% vs 7.2%), and gastrointestinal (8.7% vs 8.3%); only 50.2% and 73.3% reported no symptoms at all. Symptoms of post-infectious syndromes were similarly prevalent among the COVID+ and COVID− groups at 3 months. Conclusions Approximately half of COVID+ participants, as compared with one-quarter of COVID− participants, had at least 1 SARS-CoV-2 symptom at 3 months, highlighting the need for future work to distinguish long COVID. Clinical Trials Registration NCT04610515. Among persons testing for acute viral symptoms suggestive of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emergent/persistent symptoms at 3 months were common, reported by approximately half of coronavirus disease (COVID)+ participants and one-quarter of COVID− participants. Post-infectious syndromes were equally common in both groups at 3 months, highlighting the challenges in identifying symptoms specific for long COVID and the importance of longitudinal studies includi
ISSN:1058-4838
1537-6591
1537-6591
DOI:10.1093/cid/ciac966